In a patient with coronary artery disease who is taking rosuvastatin 5 mg daily with an LDL‑C of 60 mg/dL, should an additional medication be added to provide extra anti‑inflammatory benefit?

Adding Anti-Inflammatory Therapy in CAD with Optimal LDL-C

Yes, consider adding low-dose colchicine (0.5 mg daily) to provide additional anti-inflammatory benefit in your patient with coronary artery disease, even though their LDL-C is already at goal on rosuvastatin 5 mg daily.

Guideline-Based Recommendation

The 2024 ESC guidelines explicitly state that in patients with chronic coronary syndrome and atherosclerotic CAD, low-dose colchicine (0.5 mg daily) should be considered (Class IIa, Level A) to reduce myocardial infarction, stroke, and need for revascularization 1. This recommendation is independent of LDL-C levels and represents recognition of residual inflammatory risk beyond lipid control.

The Rationale: Residual Inflammatory Risk

Your patient exemplifies a critical clinical scenario: despite achieving excellent LDL-C control at 60 mg/dL (well below the <70 mg/dL or <55 mg/dL targets), they still carry residual cardiovascular risk. This "residual inflammatory risk" persists even with optimal lipid management and represents a therapeutic target that statins alone cannot fully address.

Why Colchicine?

• Mechanism: Colchicine provides anti-inflammatory effects through multiple pathways distinct from statin pleiotropic effects, targeting the inflammasome and reducing inflammatory cytokines
• Evidence base: The Class IIa recommendation is supported by Level A evidence, indicating multiple high-quality randomized trials demonstrating cardiovascular benefit
• Additive benefit: The anti-inflammatory effect complements rather than duplicates the lipid-lowering achieved by rosuvastatin

Clinical Implementation

Dosing: 0.5 mg once daily 1

When to add:

• Patient already on stable statin therapy with LDL-C at or near goal
• Documented atherosclerotic CAD (your patient qualifies)
• No contraindications to colchicine

Monitoring considerations:

• Check baseline renal function (colchicine requires dose adjustment or avoidance in severe renal impairment)
• Monitor for gastrointestinal side effects (diarrhea is most common)
• Be aware of drug interactions, particularly with strong CYP3A4 inhibitors

Important Caveats

What About Intensifying Lipid Therapy Instead?

While your patient is on rosuvastatin 5 mg with LDL-C of 60 mg/dL, you might consider whether to intensify lipid therapy before adding anti-inflammatory therapy:

• Current guidelines recommend LDL-C <55 mg/dL for very high-risk patients 1
• If your patient has had prior MI or multiple risk factors, consider increasing rosuvastatin dose or adding ezetimibe to achieve LDL-C <55 mg/dL first
• The 2024 ESC guidelines recommend combination therapy (statin + ezetimibe, with PCSK9 inhibitor if needed) for patients not achieving <55 mg/dL 1

The Hierarchy of Therapy

Optimal approach:

1. First priority: Ensure LDL-C is at appropriate target (<55 mg/dL for very high risk, <70 mg/dL for high risk)
2. Second priority: Once lipid goals achieved, add colchicine for residual inflammatory risk reduction
3. Consider: Whether your patient qualifies as "very high risk" (prior MI, diabetes, multiple vascular beds) requiring the more aggressive <55 mg/dL target

Practical Algorithm

For your specific patient:

• If very high risk (prior MI, diabetes, or multiple risk factors):

  • Intensify lipid therapy first: increase rosuvastatin to 10-20 mg or add ezetimibe to achieve LDL-C <55 mg/dL
  • Then add colchicine 0.5 mg daily for anti-inflammatory benefit

• If high risk but not very high risk:

  • Current LDL-C of 60 mg/dL is acceptable
  • Add colchicine 0.5 mg daily now for anti-inflammatory benefit

Common Pitfalls to Avoid

• Don't assume statin anti-inflammatory effects are sufficient: While statins have pleiotropic effects including CRP reduction 2, 3, colchicine provides additional inflammatory risk reduction through different mechanisms
• Don't neglect other risk factors: Ensure blood pressure control, antiplatelet therapy, and lifestyle modifications are optimized
• Don't forget drug interactions: Rosuvastatin has multiple interactions 4; ensure no contraindications before adding colchicine

The evidence strongly supports targeting residual inflammatory risk in CAD patients with established atherosclerosis, making colchicine a reasonable addition to your patient's regimen 1.